Aptamer Group PLC

APTA

Equity

ISIN GB00BNRRP542 / Valor 115383974

LSE London Stock Exchange, SETS (2025-12-19)

GBP 0.0075-6.25%

Aptamer Group PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Aptamer Group PLC specializes in the discovery and development of Optimer binders, which are advanced aptamers designed to offer high affinity, specificity, and stability. These binders are cost-effective and are utilized in various applications across the life sciences sector, including therapeutic, diagnostic, and target-binding solutions. The company leverages its extensive experience and employs cutting-edge, high-throughput automated technologies to provide customized aptamer-based solutions to a global clientele. Aptamer Group's innovative approach aims to facilitate advancements in the life sciences by enhancing the performance and efficiency of molecular binding processes.

Summarized from source with an LLMView SourceSector: Technology

Financial Performance

The company reported revenue of £0.9 million for 2024, down from £1.8 million in 2023, while the cash balance improved to £0.9 million from £0.2 million. Adjusted EBITDA loss was reduced to £2.8 million compared to £4.7 million, and administration expenses dropped to £3.2 million from £5.0 million.

Strategic and Commercial Developments

Aptamer Group PLC focused on a new strategic approach emphasizing the development and partnering of high-value Optimer assets with licensing potential. Key milestones include winning £1.0 million in orders in the last quarter and progressing licensing discussions with a top five pharmaceutical partner, alongside targeted partnerships with Unilever, AstraZeneca, and other industry leaders.

Organisational Restructure and Future Outlook

The Group underwent a reorganisation with a refreshed Board and key executive appointments, positioning itself for enhanced cost management and strategic asset development. The successful equity raise and continued contract wins signal a promising trajectory as the Company leverages its innovative Optimer platform to secure future high-value deals.

Summarized from source with an LLMView Source

Key figures

108%1Y

-98.8%3Y

%5Y

Performance

95.5%1Y

152%3Y

136%5Y

Volatility